BioXcel LLC utilizes advanced technologies such as AI (Artificial Intelligence) to develop transformative medicines at unprecedented speed in multiple therapeutic areas with high unmet needs. BioXcel is optimizing research and development for productivity and creating novel and transformative medicines (or drugs). BioXcel's AI-enabled platform, EvolverAI helps reduce development costs and accelerates the drug development timelines for a technologically-enabled, fast and efficient drug discovery process.
Looking for a particular BioXcel, LLC employee's phone or email?
The BioXcel, LLC annual revenue was $18.8 million in 2026.
Frank Yocca is the Chief Scientific Officer of BioXcel, LLC.
39 people are employed at BioXcel, LLC.
BioXcel, LLC is based in New Haven, Connecticut.
The NAICS codes for BioXcel, LLC are [32541, 325, 3254, 54, 32, 541].
The SIC codes for BioXcel, LLC are [283, 87, 873, 28].